Coverage Rights — Knee injection denial evidence checklist

Sources reviewed 2026-09-05

U.S. self-help preparation for knee osteoarthritis injection denials; not medical or legal advice. The historical California review rate is not your chance of success. L39260 is a local Medicare policy, not a nationwide rule for every plan. Confirm contractor jurisdiction, service date, and the policy in your notice. Clinical guidance and FDA labeling do not guarantee insurance coverage.


1. The denial and the applicable rule
Keep the complete notice, notice date, filing deadline, recipient, and the exact plan policy or criterion cited. Ask which benefit covers the injection and whether the dispute is medical necessity, a preferred product, repeat timing, or a billing issue.
Evidence / questions for clinician: ____________________


2. Diagnosis, knee, and functional limits
Ask the clinician to identify the affected knee, diagnosis, relevant imaging report, and how pain limits walking, standing, or other daily activities. Do not infer a diagnosis from pain alone.
Evidence / questions for clinician: ____________________


3. Conservative care already tried
List each treatment, dates, duration, response, and adverse effects. Include non-drug approaches and medicines where relevant. Ask the clinician to explain any contraindication instead of treating a contraindicated therapy as a required trial.
Evidence / questions for clinician: ____________________


4. Why this product and this request
Ask the prescriber to answer the actual denial criterion, explain the individual rationale, and check the requested dose and schedule against current product labeling. Approval of one hyaluronic-acid product does not establish coverage for every product.
Evidence / questions for clinician: ____________________


5. If this is a repeat series
Record prior injection dates, which knee was treated, measurable pain and function changes, when symptoms returned, and why the timing satisfies the applicable policy. A first series and a repeat series can have different criteria.
Evidence / questions for clinician: ____________________


6. A complete submission record
Match each disputed criterion to an attachment. Confirm the governing appeal route, send it using the notice instructions, and keep the submission receipt. Ask the clinician about an urgent review if waiting could seriously harm health.
Evidence / questions for clinician: ____________________


Clinical context: AAOS does not recommend hyaluronic-acid injections for routine knee osteoarthritis use. Ask the clinician to address the limitations and the individual rationale.


Policy example: L39260 includes imaging-supported symptomatic knee OA, conservative-care requirements, and separate repeat-series criteria. Read the full applicable policy; this checklist is not a coverage determination.


Sources:

FDA: Monovisc approval record and labeling: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P090031

CMS: local coverage determination L39260: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39260

AAOS: knee osteoarthritis clinical guideline: https://www.aaos.org/quality/quality-programs/osteoarthritis-of-the-knee/


Choose your appeal route: https://www.coverage-rights.com/tools/explain-my-denial


Keep completed copies private. No account or payment is required for this blank checklist.